Tag: Atlanta Talcum Powder lawyer

Talcum Powder Lawyers Win | Talc Lawsuit Alert

Talcum Powder Lawyers Win For Ovarian Cancer Victim

J&J  Has Been Ordered to Pay $417 Million

(Reuters) – A California jury on Monday ordered Johnson & Johnson to pay $417 million to a woman who claimed she developed ovarian cancer after using the company’s talc-based products like Johnson’s Baby Powder for feminine hygiene.
The Los Angeles Superior Court jury’s verdict in favor of California resident Eva Echeverria was the largest yet in lawsuits alleging J&J failed to adequately warn consumers about the cancer risks of its talc-based products.
“We are grateful for the jury’s verdict on this matter and that Eva Echeverria was able to have her day in court,” Mark Robinson, her lawyer, said in a statement.
The verdict included $70 million in compensatory damages and $347 million in punitive damages. It was a major setback for J&J, which faces 4,800 similar claims nationally and has been hit with over $300 million in verdicts by juries in Missouri.
“We will appeal today’s verdict because we are guided by the science, which supports the safety of Johnson’s Baby Powder,” J&J said.
Echeverria’s lawsuit was the first out of hundreds of California talc cases to go to trial.
The 63-year-old claimed she developed terminal ovarian cancer after decades of using J&J’s products. Her lawyers argued J&J encouraged women to use its products despite knowing of studies linking ovarian cancer to genital talc use.
J&J’s lawyers countered that studies and federal agencies have not found that talc products are carcinogenic.
The trial follows five prior ones in Missouri state court, where many lawsuits are pending.
J&J lost four of those trials and, along with a talc supplier, has been hit with $307 million in verdicts. Before Monday, the largest verdict was for $110 million.
The Missouri cases, which have largely been brought by out-of-state plaintiffs, have faced jurisdictional questions after the U.S. Supreme Court issued a ruling in June that limited where personal injury lawsuits can be filed.
In a decision in a case involving Bristol-Myers Squibb Co, the Supreme Court said state courts cannot hear claims against companies that are not based in the state when the alleged injuries did not occur there.
The ruling prompted a St. Louis judge, at New Jersey-based J&J’s urging, to declare a mistrial in the talc case already underway.
The judge has nonetheless left the door open for the plaintiffs to argue they still have jurisdiction based on a Missouri-based bottler J&J used to package its products.
The case is Echeverria et al v. Johnson & Johnson, Los Angeles Superior Court, No. BC628228.
(Reporting by Nate Raymond in Boston; Editing by Matthew Lewis and Paul Simao)

If you or a loved one used  Johnson and Johnson Talcum Powder  products for over five years on or near the genital area and now have a diagnosis of ovarian cancer or fallopian tube cancer contact The Talcum Powder Lawyer Helpline today.

Talcum Powder Cancer Lawsuits Continue

Johnson and Johnson Facing Potentially  1000’s Of Ovarian Cancer Lawsuits

Johnson and Johnson won a  fourth talcum powder lawsuit but, had  three judgements of $72 million, $70 million and $55 million. Our lawyers have filed dozens of talcum powder lawsuits  on behalf of women who claim they got  ovarian cancer from Johnson & Johnson’s talcum based powders. A fifth talcum baby powder lawsuit was heard in the 22nd Circuit Court in St. Louis, Missouri, on April 10th. The jury heard the case of Lois Slemp, who alleges that she developed ovarian cancer as a result of long term use of talc powder found in feminine hygiene products made by Johnson & Johnson (J&J).

A California state court judge will convene a 5-day “Sargon” hearing, California’s equivalent of a Daubert proceeding, to determine the admissibility of expert witness testimony. This could be as significant as a trial itself, after a New Jersey state court judge in October nixed testimony from two key expert witnesses for the plaintiff, scuttling what was set to the first talcum powder trial in the state. That decision remains on appeal.

Depending on the outcome of the June hearing, a bellwether trial is scheduled for July in Los Angeles, along with another trial scheduled that same month in Washington D.C. Superior Court. .

The case is captioned Valerie Swann, et al. v. Johnson & Johnson, et al. case number 1422 CC09326-01 in Missouri’s 22nd Judicial Circuit Court.

Talcum powder cases continue in Federal court. About 134 cases are on file in the District of New Jersey Federal Court. The parties have been discussing various topics, including a protective order, a preservation order and other legal issues. A preservation order is where a plaintiff has to store physical or biological evidence for use in trials.

Johnson & Johnson reported in a recent filing with the U.S. Securities & Exchange Commission (SEC) that it has been named a defendant in at least 3,100 product liability claims. These lawsuits are claims by women that Baby Powder and Shower-to-Shower talc-based powders contributed to them getting ovarian cancer.

If you think you have a diagnosis of ovarian cancer due to your use of Baby Powder or Shower To Shower contact us today

 

What Is Talc?

Talcum Powder Lawsuit Helpline is always seeking articles we believe will be of interest to our readers.  Talcum Powder  products causing ovarian cancer have resulted in an onslaught of lawsuits across the country. Talcum Powder is made from Talc. But, what exactly is Talc?
Talc is a hydrous magnesium silicate mineral with a chemical composition of Mg3Si4O10(OH)2. If you are not a chemist you probably have no idea what that means. In lay terms, Talcum powder is made from talc. Talc is a mineral made up of  magnesium, silicon, and oxygen. Talc is usually green, white, gray, brown, or colorless. It is a translucent mineral with a pearly luster.

About Talc In the US

The United States is self-sufficient for most types of talc used in manufacturing. Estimated 2011 production was 615,000 metric tons with a value of about $20 million. Three companies in the United States account for nearly 100% of the country’s production.

How Does Talc Form?
Talc is a mineral that is most often found in the metamorphic rocks of convergent plate boundaries. It forms from at least two processes. Most large talc deposits in the United States formed when heated waters carrying dissolved magnesium and silica reacted with dolomitic marbles. A second process of talc formation occurred when heat and chemically active fluids altered rocks such as dunite and serpentinite into talc.
Talc Mining In The US
Most talc in the United States is produced from an open pit mine where the rock is drilled, blasted, and partially crushed in the mining operation. The highest grade ores are produced by selective mining and sorting operations.

Great care is taken during the mining process to avoid contaminating the talc with other rock materials. These other materials can have an adverse effect on the color of the product. Contamination can introduce hard particles that cause problems in applications where talc is being used because of its softness or lubricating properties.

Partially crushed rock is taken from the mine to a mill, where it is further reduced in particle size. Impurities are sometimes removed by froth flotation or mechanical processing. The mills produce crushed or finely ground talc that meets customer requirements for particle size, brightness, composition, and other properties.
Uses of Talc: Talc is used as a filler, coating, pigment, dusting agent and extender in plastics, ceramics, paint, paper, cosmetics, roofing, rubber and many other products.

Talc Information

U.S. Talc — Baby Powder and Much More: U.S. Geological Survey, Fact Sheet FS-065-00, September 2000.

Talc in Cosmetics: United States Food and Drug Administration, website article, last accessed August 2016.

Use Of Talc in Cosmetics and Antiperspirants
Finely ground talc is used as the powder base of many cosmetic products. The tiny platelets of a talc powder readily adhere to the skin but can be washed off easily. Talc’s softness allows it to be applied and removed without causing skin abrasion.

Talc also has the ability to absorb oils and perspiration produced by human skin. The ability of talc to absorb moisture, absorb odor, adhere to the skin, serve as a lubricant, and produce an astringent effect in contact with human skin make it an important ingredient in many antiperspirants. In 2011, about 7% of the talc consumed in the United States was used to make cosmetics and antiperspirant.

Talc and asbestos occur naturally and may occur in close proximity in some metamorphic rocks. Studies published in the 1960s and 1970s identified health concerns about the use of talc that contains asbestos in some cosmetic products.

According to the FDA, “These studies have not conclusively demonstrated such a link, or if such a link existed, what risk factors might be involved.” To address these concerns, talc mining sites are now carefully selected and ores are carefully processed to avoid the presence of asbestos in talc destined for use in the cosmetics industry.

Talc used in Talcum powder has been associated with the development of ovarian cancer due to inflammation

 

 

Latest Research on Ovarian Cancer

The Talcum Powder Lawsuit Helpline is more then just a network of experienced Talcum Powder Lawsuit Attorneys. We offer ovarian cancer resources and updates that are found online. Below you will find some of the latest research on ovarian cancer. It is now known, that the manufacturers knew that there was a potential link between ovarian cancer and the use of Talcum Powder and Baby Powder. The jury knew it when they gave the family of a talcum powder- ovarian cancer victim $72 million.

We found this page on the latest research and offer it to our followers. We hope this helps.

Ovarian Cancer – Latest Research
Approved by the Cancer.Net Editorial Board, 04/2015

Doctors are working to learn more about ovarian cancer, ways to prevent it, how to best treat it, and how to provide the best care to people diagnosed with this disease. The following areas of research may include new options for patients through clinical trials. Always talk with your doctor about the diagnostic and treatment options best for you.

Screening For Ovarian Cancer

There are no currently effective screening methods for the general population. A screening method that estimates a woman’s risk of ovarian cancer by using her age and the results of a yearly CA-125 blood test holds promise for detecting early-stage ovarian cancer. An international study is looking into the role of serial CA-125 screening for ovarian cancer. As explained in Diagnosis, CA-125 is a substance called a tumor marker that is found in higher levels in women with ovarian cancer.

In 2012, the U.S Preventative Services Task Force released a statement saying that for the general population of women with no symptoms, screening for ovarian cancer is not helpful and may lead to harm. However, women at high risk for ovarian cancer due to family history or with a BRCA mutation(s) (see Risk Factors) are recommended to have screening with CA-125 blood tests and transvaginal ultrasound. This approach has not been proven to improve survival or detect cancers at an earlier and more curable stage.

Targeted Therapy For Ovarian Cancer

Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.

Some targeted therapy is directed towards specific genes that might be found with abnormalities in certain types of epithelial ovarian cancer. For this purpose, ovarian cancer is divided into two groups:  type I and type II.  Type II cancers are the more typical high grade serous cancers, for which standard chemotherapy has been most effective. These tumors typically are diagnosed at later stages and have mutations in TP53 and BRCA genes in the tumor.  Other mutations are rarely seen.

The BRCA mutation, even if only found in the tumor and not in the blood, may increase the effectiveness of a certain classes of drugs such as PARP inhibitors (see below).  Type I tumors include the more rare types of ovarian cancer including low grade serous, endometrioid, clear cell, and mucinous cancers.  These tumors have a variety of mutations including KRAS, BRAF, PI3KCA and PTEN, which have implications for targeted treatment. Clinical trials in these groups are ongoing.

Anti-Angiogenesis Inhibitors For Ovarian Cancer

Drugs called anti-angiogenesis inhibitors block the action of a protein called vascular endothelial growth factor (VEGF). These drugs have been shown to increase the cancer’s response to treatment and delay the time it takes for the cancer to return. VEGF promotes angiogenesis, which is the formation of new blood vessels. Because a tumor needs nutrients delivered by blood vessels to grow and spread, the goal of anti-angiogensis therapies is to “starve” the tumor. Bevacizumab (Avastin), an antibody which binds VEGF and prevents it from being active, has been shown to be effective in ovarian cancer.  FDA approval was recently given in the United States for its use in combination with selected chemotherapy for patients with platinum resistant recurrence.
PARP Inhibitors For Ovarian Cancer

Another class of drugs, called PARP inhibitors, are being evaluated for ovarian cancer.  These drugs act on DNA repair in cancer cells, making it difficult for them to replicate.  The BRCA genes (BRCA1 and BRCA2) are also normally involved in DNA repair, and a mutation in these genes interfere with this pathway function.  PARP inhibitors make it particularly difficult for cells that otherwise have a BRCA mutation to grow and divide.

The PARP inhibitor olaparib (Lynparza) has received FDA approval in the United States for recurrent disease in patients who have the inherited BRCA mutation and who have received three or more lines of chemotherapy.  In the supporting study of 137 patients with a BRCA mutation, 34% of patients experienced shrinkage in tumor for an average of 7.9 months. A very small number of patients developed secondary hematologic (blood) cancers after use of these drugs. Studies are currently underway with other PARP inhibitors, which do not all require the inherited BRCA mutation. These are being tested to see if they can keep the cancer from coming back after chemotherapy. The potential benefits and risks of PARP therapy should be discussed with your doctor.
Many other new targeted treatments are also now in clinical trials. Increasingly, doctors are learning about each patient’s individual tumor’s biology through direct molecular testing. This information may be useful in matching patients with a clinical trial for a specific targeted therapy.  Learn more about the basics of targeted therapy.

Immunotherapy For Ovarian Cancer

Immunotherapy is usually designed to boost the body’s natural defenses to fight the cancer. It uses materials made either by the body or in a laboratory to bolster, target, or restore immune system function. Researchers are currently examining whether drugs called checkpoint inhibitors may boost the immune system’s ability to destroy cancer cells.  Examples of these drugs target CTLA4 or PD-1 and have recently been shown to cause shrinkage in other cancer types such as melanoma, as well as having some activity in patients with ovarian cancer.

Cancer vaccines are another type of immunotherapy currently being tested for ovarian cancer.  In addition, some approaches called “adoptive cell therapy” take killer T cells found as part of the immune system in an individual patient and grow them in the laboratory, train them to attack certain targets such as MUC 16 (CA125) that is found on any ovarian cancer cells, and them give them back intravenously to the patient.  This approach has been tried in patients with hematologic cancers using other targets with some early success, and clinical trials are now opening for ovarian cancer.  Learn more about the basics of immunotherapy.

Hormone Therapy For Ovarian Cancer

Research is underway about the role of estrogen, androgens, and other hormones in ovarian cancer treatment. For treatment of recurrent or later-stage ovarian cancer,  the use of tamoxifen (Nolvadex, Soltamax), aromatase inhibitors, and enzalutamide (Xtandi), a blocker of the androgen receptor, is being considered.

Gene Therapy For Ovarian Cancer

One new area of research is discovering how damaged genes in ovarian cancer cells can be corrected or replaced. Researchers are studying the use of specially designed viruses that carry normal genes into the core of cancer cells and then replace the defective genes with the functional ones.

Supportive Care For Ovarian Cancer

Clinical trials are underway to find better ways of reducing symptoms and side effects of current ovarian cancer treatments, in order to improve a woman’s comfort and quality of life.

We will continue to search the net for ovarian cancer  information to help our clients. Our goal is to offer information that may help

 

Did Talcum Powder Ads Target Afro American Women?

The Talcum Powder Lawsuit Helpline is not just a network of Talcum Powder lawyers. We keep you updated on the latest news and articles of interest related to ovarian cancer and the talcum powder lawsuits. We are sharing this article because we feel it is of interest to women.
Johnson and Johnson has been  accused of aggressively marketing  their Baby Powder products to the  to African-American women after  sales to white women dropped off. The most recent $72 million ovarian cancer settlement was awarded to the family of an Afro American woman who used the product for feminine hygiene for decades.

It appears that  Johnson & Johnson has long been aware of the connection between talcum powder and ovarian cancer. The lawyer on the recent case  spoke to the  Atlanta Black Star, Onder said, “The evidence is real clear that Johnson & Johnson has known about the dangers associated with talcum powder for over 30 years…instead of giving a warning, what they did was target the groups most at risk for developing ovarian cancer” – in this case, black women.

Omise’eke Natasha Tinsley, a professor of African Studies at the University of Texas and contributing writer to Time magazine, points out that “Corporations have long taken advantage of the beauty rituals that African American women love.”  In a recent article, she writes, “Like pressing our hair and lotioning our legs, douching and deodorizing vaginas is something black women teach our daughters and sister-friends teach our friends.” According to research cited by Tinsley, black women employ talcum powder for such purposes twice as much as their white counterparts.

In another article published in a 2011 issue of Advertising and History Review, historian Michelle Ferranti points out that such practices have their origins in racial stereotypes and racist perceptions going back hundreds of years.  Tinsley herself adds,

Johnson & Johnson and other companies are ready to profit from these myths of the excessive black vagina. They’re willing to capitalize on our internalized misogynoir even if we die in the process. For decades, companies, including Johnson & Johnson, continued marketing to encourage black women to spend money on talcum power, which could cause cancer in our reproductive organs even as they promise to ‘freshen’ them. Because buyers were women, they were the advertisers’ targets; because they were women, they were vulnerable to side effects the companies never exposed.
A recent study from the University of Virginia, published in Cancer Epidemiology, now indicates that women who consistently apply talcum powder to their genitalia run a 40% risk of contracting ovarian cancer. Lead researcher Joellen Schildkraut said she was a skeptic until the recent studies were published.  “As you look across all these studies, I would say, why use it? It’s an avoidable risk for ovarian cancer,” she acknowledged.

Apparently Johnson and Johnson continues in it’s marketing campaigns to target women for financial and as the article continues to tell us…..gain Unfortunately, few if any consumers of all ethnic backgrounds have been aware of those risks – and in the case of the African-American community, there is decades of cultural conditioning and expectations passed from one generation to the next. That is something that Johnson & Johnson was all-too-willing to exploit.

Johnson & Johnson is unrepentant, and plans to appeal the most recent ruling. In a statement to the press, J&J spokesperson Carol Goodrich said, “the jury’s decision goes against 30 years of studies by medical experts around the world that continue to support the safety of cosmetic talc.”

If you or a loved one has ovarian cancer and used Talcum powder, Baby Powder or Talc Powder for years contact out Talcum Powder Helpline. Speak to a medical social worker and Talcum Powder lawyer.

 

What Is Talcum Powder?

What is Talcum Powder?
Talcum powder is made from talc, a mineral made up mainly of the elements magnesium, silicon, and oxygen. As a powder, it absorbs moisture well and helps cut down on friction, making it useful for keeping skin dry and helping to prevent rashes. It is widely used in cosmetic products such as baby powder and adult body and facial powders, as well as in a number of other consumer products.

In its natural form, some talc contains asbestos, a substance known to cause cancers in and around the lungs when inhaled (see our document Asbestos). All talcum products used in homes in the United States have been asbestos-free since the 1970s.

Talc, from which talcum powder is developed has been used by women to dry off in the pelvic area on a daily basis. New research links talc to ovarian cancer, and women are  filing Talcum Powder lawsuits against the manufacturers.

Who would believe it. Johnson and Johnson baby talcum  powder lawsuits for ovarian cancer. Yes it is true.  Contact the Talcum Powder-Ovarian Cancer Lawsuit Helpline today.